Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.

ABSTRACT:

Background

The recently emerged SARS-CoV-2 Omicron variant exhibits several mutations on the spike protein, enabling it to escape the immunity elicited by natural infection or vaccines. Avidity is the strength of binding between an antibody and its specific epitope. The SARS-CoV-2 spike protein binds to its cellular receptor with high affinity and is the primary target of neutralizing antibodies. Therefore, protective antibodies should show high avidity. This study aimed at investigating the avidity of receptor-binding domain (RBD) binding antibodies and their neutralizing activity against the Omicron variant in SARS-CoV-2 infected patients and vaccinees.

Methods

Samples were collected from 42 SARS-CoV-2 infected patients during the first pandemic wave, 50 subjects who recei

SUBMITTER: Dapporto F 

PROVIDER: S-EPMC9453088 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature